01—Abstract
Summary
Summary of the 8-K filed July 9, 2025. Cited figures are marked; the original filing is the authoritative source.
Marsh & McLennan Companies, Inc. filed a Form 8-K on July 9, 2025 to report the appointment of Bruce Broussard, age 63, as an independent member of its Board of Directors, effective immediately.
The Board also named him to the Audit Committee, determining that he meets all applicable requirements, including independence standards. The filing is a governance update and contains no financial results, guidance, or material financial impact. Broussard brings more than 30 years of healthcare leadership.
He was President of Humana from 2011 and its CEO from 2013 to 2024, and earlier held CEO and CFO roles at McKesson Specialty/US Oncology. He also sits on the boards of HP Inc., Cleveland Clinic, and One Call. Management framed the appointment around insurance and healthcare expertise and executive finance experience.
Following the appointment, the Board has 12 directors. His addition to the Audit Committee is the most relevant item for investors, since it strengthens oversight of financial reporting and controls.
As a non-management director, Broussard will receive compensation under the company's existing independent director arrangements, which were previously disclosed as an exhibit to the Q2 2024 Form 10-Q. The filing does not specify new compensation terms or equity grants tied to this appointment.
02—Key points
Key Highlights
- Bruce Broussard, age 63, was appointed as an independent director effective July 9, 2025, bringing the Board to 12 members.
- Broussard was also appointed to the Audit Committee, with the Board determining he meets all applicable independence and qualification requirements.
- Broussard was CEO of Humana from 2013 to 2024 and President from 2011, giving him substantial insurance and healthcare industry experience.
- His prior CFO and CEO roles at US Oncology and McKesson Specialty add executive financial leadership experience relevant to audit oversight.
- Broussard currently serves on the boards of HP Inc., Cleveland Clinic, and One Call.
- Compensation follows the existing non-management director arrangements previously filed in the Q2 2024 Form 10-Q; no new pay terms were disclosed.
- The filing contains no financial results, guidance, or financial statements, so it has no direct near-term earnings impact.
03—Questions
Frequently Asked Questions
Does this board appointment affect the company's financial results or outlook?
No. The 8-K is a governance disclosure only. It reports no revenue, earnings, guidance, or other financial metrics, and it does not indicate any change to the company's financial position.
Why is Broussard's Audit Committee seat significant?
Audit Committee members oversee financial reporting, internal controls, and the external audit. The Board determined he meets independence and other requirements for this role. His background as a former CFO and CEO of large healthcare organizations may add relevant financial oversight experience.
Is Broussard considered independent?
Yes. The Board determined that he is an independent director and satisfies applicable independence standards, which is required for Audit Committee service.
How will Broussard be compensated?
He will receive compensation under the company's standard non-management director arrangements, described in the company's Q2 2024 Form 10-Q (Exhibit 10.1). The 8-K does not disclose any new or special compensation, equity award, or sign-on terms.
Are there any potential conflicts of interest to watch for?
The filing does not disclose any related-party transactions or conflicts. Investors may still note that Broussard serves on other public and nonprofit boards, which the company has presumably reviewed under its governance policies, though the filing does not address this directly.
04—Continue